{
    "info": {
        "nct_id": "NCT05325866",
        "official_title": "A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)",
        "inclusion_criteria": "1. Age ≥ 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed\n2. Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.\n\n   * head and neck squamous cell carcinoma: ≥ 1 line of therapy\n   * triple-negative breast cancer: ≥ 2 lines of therapy\n   * Intrahepatic cholangiocarcinoma ≥ 1 line of therapy\n   * lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy\n   * platinum resistant ovarian epithelial cell carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy\n   * endometrial adenocarcinoma: ≥ 1 line of therapy\n   * cervical carcinoma: ≥ 1 line of therapy\n   * other solid tumors: ≥ 1 line of therapy\n3. Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)\n4. Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing\n5. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1\n6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n7. Adequate organ function as determined per protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 99 Years",
        "exclusion_criteria": "1. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.\n2. Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma\n3. Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction ≥ 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval QTc ≥ 470\n4. History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids\n5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing\n6. Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment\n7. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy\n8. Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication).",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* head and neck squamous cell carcinoma: ≥ 1 line of therapy",
            "criterions": [
                {
                    "exact_snippets": "head and neck squamous cell carcinoma",
                    "criterion": "head and neck squamous cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 1 line of therapy",
                    "criterion": "lines of therapy received",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 99 Years",
            "criterions": [
                {
                    "exact_snippets": "Must have maximum age of 99 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 99,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* triple-negative breast cancer: ≥ 2 lines of therapy",
            "criterions": [
                {
                    "exact_snippets": "triple-negative breast cancer",
                    "criterion": "triple-negative breast cancer",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 2 lines of therapy",
                    "criterion": "lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. Tumor overexpresses FGFR2b as determined by centrally performed immunohistochemistry (IHC) testing",
            "criterions": [
                {
                    "exact_snippets": "Tumor overexpresses FGFR2b",
                    "criterion": "FGFR2b expression in tumor",
                    "requirements": [
                        {
                            "requirement_type": "expression level",
                            "expected_value": "overexpression"
                        }
                    ]
                },
                {
                    "exact_snippets": "as determined by centrally performed immunohistochemistry (IHC) testing",
                    "criterion": "FGFR2b expression assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "centrally performed immunohistochemistry (IHC) testing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* lung adenocarcinoma: at least platinum-based chemotherapy, checkpoint inhibitor, and targeted therapy",
            "criterions": [
                {
                    "exact_snippets": "lung adenocarcinoma",
                    "criterion": "lung adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least platinum-based chemotherapy",
                    "criterion": "platinum-based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "checkpoint inhibitor",
                    "criterion": "checkpoint inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "targeted therapy",
                    "criterion": "targeted therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Age ≥ 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed",
            "criterions": [
                {
                    "exact_snippets": "Age ≥ 18 years (or legal adult age within country, whichever is older) at the time that the Informed Consent Form (ICF) is signed",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum age",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 18,
                                        "unit": "years"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "legal adult age within country"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Disease that is unresectable, locally advanced, or metastatic (not amenable to curative therapy)",
            "criterions": [
                {
                    "exact_snippets": "Disease that is unresectable",
                    "criterion": "disease resectability",
                    "requirements": [
                        {
                            "requirement_type": "resectability",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "locally advanced",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "locally advanced"
                        }
                    ]
                },
                {
                    "exact_snippets": "metastatic",
                    "criterion": "disease stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "metastatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "not amenable to curative therapy",
                    "criterion": "amenability to curative therapy",
                    "requirements": [
                        {
                            "requirement_type": "amenability to curative therapy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* endometrial adenocarcinoma: ≥ 1 line of therapy",
            "criterions": [
                {
                    "exact_snippets": "endometrial adenocarcinoma: ≥ 1 line of therapy",
                    "criterion": "endometrial adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "lines of therapy received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Adequate organ function as determined per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function as determined per protocol",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per Response Evaluation Criteria in Solid Tumors Version 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment method",
                            "expected_value": "Response Evaluation Criteria in Solid Tumors Version 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* cervical carcinoma: ≥ 1 line of therapy",
            "criterions": [
                {
                    "exact_snippets": "cervical carcinoma: ≥ 1 line of therapy",
                    "criterion": "cervical carcinoma prior therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines of therapy",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Intrahepatic cholangiocarcinoma ≥ 1 line of therapy",
            "criterions": [
                {
                    "exact_snippets": "Intrahepatic cholangiocarcinoma",
                    "criterion": "intrahepatic cholangiocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 1 line of therapy",
                    "criterion": "prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of prior lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* other solid tumors: ≥ 1 line of therapy",
            "criterions": [
                {
                    "exact_snippets": "other solid tumors: ≥ 1 line of therapy",
                    "criterion": "prior lines of therapy for other solid tumors",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line of therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* platinum resistant ovarian epithelial cell carcinoma, including fallopian tube cancers and primary peritoneal cancers, defined as progression during or within 6 months of a platinum containing regimen: ≥ 1 line of therapy",
            "criterions": [
                {
                    "exact_snippets": "platinum resistant ovarian epithelial cell carcinoma",
                    "criterion": "ovarian epithelial cell carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "platinum resistance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "including fallopian tube cancers and primary peritoneal cancers",
                    "criterion": "cancer type",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "fallopian tube cancer",
                                "primary peritoneal cancer"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "defined as progression during or within 6 months of a platinum containing regimen",
                    "criterion": "disease progression after platinum regimen",
                    "requirements": [
                        {
                            "requirement_type": "progression timing",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 6,
                                        "unit": "months"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "≥ 1 line of therapy",
                    "criterion": "number of prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "line"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Histologically or cytologically confirmed cancer of one of the following types, refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting, as specified below. If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor. Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.",
            "criterions": [
                {
                    "exact_snippets": "Histologically or cytologically confirmed cancer of one of the following types",
                    "criterion": "cancer diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "histological",
                                "cytological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "refractory to or relapsed after at least 1 prior standard therapeutic regimen in the advanced/metastatic setting",
                    "criterion": "response to prior standard therapeutic regimen",
                    "requirements": [
                        {
                            "requirement_type": "refractory or relapsed",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "number of prior regimens",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "regimen"
                            }
                        },
                        {
                            "requirement_type": "disease setting",
                            "expected_value": "advanced/metastatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "If no standard of care therapies exist for the participant, or the participant cannot tolerate or refuses standard of care anticancer therapy, the participant may be allowed to participate on the study after discussion between the investigator and Amgen medical monitor.",
                    "criterion": "standard of care therapy availability/tolerance/refusal",
                    "requirements": [
                        {
                            "requirement_type": "standard of care therapy existence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "tolerance to standard of care therapy",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "refusal of standard of care therapy",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants who have not received all approved or standard treatments for their cancer must be informed that these alternatives to receiving bemarituzumab are available prior to consenting to participate in the trial.",
                    "criterion": "informed of alternative treatments",
                    "requirements": [
                        {
                            "requirement_type": "information about alternatives",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "6. Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment",
            "criterions": [
                {
                    "exact_snippets": "Unwillingness to avoid use of contact lenses during study treatment and for at least 100 days after the end of treatment",
                    "criterion": "use of contact lenses",
                    "requirements": [
                        {
                            "requirement_type": "avoidance duration",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 100,
                                        "unit": "days"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "8. Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication).",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with any investigational selective inhibitor of the fibroblast growth factor (FGF)/FGF receptor pathway (unless approved standard of care for tumor indication)",
                    "criterion": "prior treatment with investigational selective FGF/FGF receptor pathway inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of prior treatment",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "drug type",
                            "expected_value": "investigational selective inhibitor of the FGF/FGF receptor pathway"
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": "unless approved standard of care for tumor indication"
                        }
                    ]
                }
            ]
        },
        {
            "line": "4. History of systemic disease or ophthalmologic disorders requiring chronic use of ophthalmic steroids",
            "criterions": [
                {
                    "exact_snippets": "History of systemic disease",
                    "criterion": "systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ophthalmologic disorders requiring chronic use of ophthalmic steroids",
                    "criterion": "ophthalmologic disorders",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "chronic use of ophthalmic steroids"
                        }
                    ]
                }
            ]
        },
        {
            "line": "1. Untreated or symptomatic central nervous system (CNS) metastases or leptomeningeal disease.",
            "criterions": [
                {
                    "exact_snippets": "Untreated ... central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "symptom status",
                            "expected_value": "symptomatic"
                        }
                    ]
                },
                {
                    "exact_snippets": "leptomeningeal disease",
                    "criterion": "leptomeningeal disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "5. Evidence of any ongoing ophthalmologic abnormalities or symptoms that are acute (within 4 weeks) or actively progressing",
            "criterions": [
                {
                    "exact_snippets": "Evidence of any ongoing ophthalmologic abnormalities or symptoms",
                    "criterion": "ophthalmologic abnormalities or symptoms",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "acute (within 4 weeks)",
                    "criterion": "ophthalmologic abnormalities or symptoms",
                    "requirements": [
                        {
                            "requirement_type": "onset_timing",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "actively progressing",
                    "criterion": "ophthalmologic abnormalities or symptoms",
                    "requirements": [
                        {
                            "requirement_type": "progression_status",
                            "expected_value": "actively progressing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "7. Recent (within 6 months) corneal surgery or ophthalmic laser treatment or recent (within 6 months) history of, or evidence of, corneal defects, corneal ulcerations, keratitis, or keratoconus, or other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy",
            "criterions": [
                {
                    "exact_snippets": "Recent (within 6 months) corneal surgery",
                    "criterion": "corneal surgery",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "ophthalmic laser treatment",
                    "criterion": "ophthalmic laser treatment",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 6 months) history of, or evidence of, corneal defects",
                    "criterion": "corneal defects",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "history_or_evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 6 months) history of, or evidence of, ... corneal ulcerations",
                    "criterion": "corneal ulcerations",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "history_or_evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 6 months) history of, or evidence of, ... keratitis",
                    "criterion": "keratitis",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "history_or_evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 6 months) history of, or evidence of, ... keratoconus",
                    "criterion": "keratoconus",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        },
                        {
                            "requirement_type": "history_or_evidence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "other known abnormalities of the cornea that may pose an increased risk of developing a corneal ulcer prior/concomitant therapy",
                    "criterion": "abnormalities of the cornea",
                    "requirements": [
                        {
                            "requirement_type": "risk_of_corneal_ulcer",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "2. Other solid tumor cohort excludes primary tumors of the CNS, squamous non-small cell lung cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma",
            "criterions": [
                {
                    "exact_snippets": "Other solid tumor cohort excludes primary tumors of the CNS",
                    "criterion": "primary tumors of the CNS",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Other solid tumor cohort excludes ... squamous non-small cell lung cancer",
                    "criterion": "squamous non-small cell lung cancer",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Other solid tumor cohort excludes ... gastric adenocarcinoma",
                    "criterion": "gastric adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Other solid tumor cohort excludes ... gastroesophageal junction adenocarcinoma",
                    "criterion": "gastroesophageal junction adenocarcinoma",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "3. Impaired cardiac function or clinically significant cardiac disease including: unstable angina within 6 months prior to first dose of study treatment, acute myocardial infarction ≥ 6 months prior to first dose of study treatment, New York Heart Association (NYHA) class II-IV congestive heart failure, uncontrolled hypertension (defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment, uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin, active coronary artery disease or corrected QT interval QTc ≥ 470",
            "criterions": [
                {
                    "exact_snippets": "Impaired cardiac function",
                    "criterion": "cardiac function",
                    "requirements": [
                        {
                            "requirement_type": "impairment",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "clinically significant cardiac disease",
                    "criterion": "cardiac disease",
                    "requirements": [
                        {
                            "requirement_type": "clinical significance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina within 6 months prior to first dose of study treatment",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "acute myocardial infarction ≥ 6 months prior to first dose of study treatment",
                    "criterion": "acute myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "New York Heart Association (NYHA) class II-IV congestive heart failure",
                    "criterion": "congestive heart failure (NYHA class)",
                    "requirements": [
                        {
                            "requirement_type": "NYHA class",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 2,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension (defined as an average systolic blood pressure ≥ 160 mmHg or diastolic ≥ 100 mmHg despite optimal treatment",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 160,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "treatment",
                            "expected_value": "despite optimal treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled cardiac arrhythmias requiring anti-arrhythmic therapy other than beta blockers or digoxin",
                    "criterion": "cardiac arrhythmias",
                    "requirements": [
                        {
                            "requirement_type": "control",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "anti-arrhythmic therapy",
                            "expected_value": "required"
                        },
                        {
                            "requirement_type": "allowed medications",
                            "expected_value": [
                                "beta blockers",
                                "digoxin"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "active coronary artery disease",
                    "criterion": "coronary artery disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "corrected QT interval QTc ≥ 470",
                    "criterion": "corrected QT interval (QTc)",
                    "requirements": [
                        {
                            "requirement_type": "QTc duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 470,
                                "unit": "ms"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}